(S1 (S (NP (NP (JJ Differential) (NNS effects)) (PP (IN of) (NP (NP (JJ chemotherapeutic) (NNS drugs)) (CC versus) (NP (DT the) (NN MDM-2) (NN antagonist) (NN nutlin-3)))) (PP (IN on) (NP (NP (NN cell) (NN cycle) (NN progression)) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NN apoptosis))) (PP (IN in) (NP (NN SKW6.4) (JJ lymphoblastoid) (NNS B-cells)))))) (. .))))
(S1 (S (NP (PRP We)) (VP (VBP have) (VP (VBN compared) (NP (NP (DT the) (JJ cytotoxic/cytostatic) (NNS responses)) (PP (IN of) (NP (DT the) (NN SKW6.4) (JJ lymphoblastoid) (NNS B-cells))) (PP (TO to) (NP (NP (DT the) (JJ alkylating) (NN agent) (NN chlorambucil)) (, ,) (NP (NP (NP (DT the) (NN purine) (NN analog) (NN fludarabine)) (, ,) (NP (NP (NP (DT the) (JJ non-genotoxic) (NN activator)) (PP (IN of) (NP (DT the) (NN p53) (NN pathway)))) (, ,) (NP (NN Nutlin-3))) (, ,)) (VP (VBN used) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (DT the) (JJ death-inducing) (NN ligand) (JJ recombinant) (NN TRAIL))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Exposure)) (PP (TO to) (NP (NP (NN chlorambucil)) (, ,) (NP (NN fludarabine)) (, ,) (CC and) (NP (NN Nutlin-3))))) (VP (VP (VBD induced) (NP (NN p53) (NN accumulation))) (CC and) (VP (ADVP (RB variably)) (VBD affected) (NP (NP (NN cell) (NN cycle) (NN progression)) (PP (IN in) (NP (NN SKW6.4) (JJ lymphoblastoid) (NNS cells))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NN chlorambucil)) (VP (VBD induced) (NP (NN cell) (NN cycle) (NN accumulation)) (PP (IN at) (NP (DT the) (NN G2/M) (NN checkpoint))))) (: ;) (S (NP (NN Nutlin-3)) (VP (VBD induced) (NP (JJ early) (NN cell) (NN cycle) (NN arrest)) (PP (IN at) (NP (DT the) (NN G1/S) (NN checkpoint))) (, ,) (SBAR (IN while) (S (NP (NN fludarabine)) (VP (VBD showed) (NP (DT an) (JJ intermediate) (NN behavior))))))) (. .)))
(S1 (S (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (JJ recombinant) (NN TRAIL)) (ADVP (RB alone)) (VP (VP (VBD did) (RB not) (VP (VB affect) (NP (NN cell) (NN cycle) (NN progression)))) (CC but) (VP (VBD induced) (NP (NP (DT a) (JJ rapid) (NN increase)) (PP (IN of) (NP (NN apoptosis))))))) (. .)))
(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (NN gene) (NN expression) (NN profile)) (PP (IN of) (NP (DT the) (JJ p53-transcriptional) (NNS targets)))))) (VP (VBD showed) (NP (NP (JJ distinct) (NNS features)) (PP (IN between) (NP (NP (NN chlorambucil)) (, ,) (NP (NN Nutlin-3)) (CC and) (NP (NN fludarabine)))) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB likely)) (VP (VBP account) (PP (IN for) (NP (NP (PRP$ their) (JJ differential) (NN effect)) (PP (IN on) (NP (NP (NN cell) (NN cycle)) (PP (IN in) (NP (NN SKW6.4) (NNS cells)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NN chlorambucil)) (VP (VBD upregulated) (NP (NP (DT the) (JJ steady-state) (NN mRNA) (NN expression)) (PP (IN of) (NP (NP (NN SFN/14-3-3sigma)) (, ,) (NP (NP (DT a) (NN gene)) (VP (VBN involved) (PP (IN in) (NP (NN G2/M) (NN cell) (NN cycle) (NN arrest)))))))))) (. .)))
(S1 (S (S (PP (IN Of) (NP (NN note))) (, ,) (NP (DT all) (NNS agonists)) (VP (VBD upregulated) (NP (NN TRAIL-R2) (NN expression)) (PP (PP (IN in) (NP (NN SKW6.4) (NNS cells))) (CC both) (PP (IN at) (NP (DT the) (NP (NP (NN mRNA)) (CC and) (NP (NN protein))) (NNS levels)))))) (. .)))
(S1 (S (S (ADVP (RB Consistently)) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NN chlorambucil)) (, ,) (NP (NN fludarabine)) (CC and) (NP (NN Nutlin-3))))) (VP (VBD enhanced) (NP (NP (NN SKW6.4) (NN sensitivity)) (PP (TO to) (NP (JJ TRAIL-mediated) (NN apoptosis)))))) (. .)))
